▎ 摘　　要

NOVELTY - Preparing and application of graphene oxide loaded hydroxycamptothecin nano-targeted drug comprises e.g. (i) using graphene oxide as a carrier to complete the preparation of nano-targeted drugs and the loading of drugs; (ii) using fluorescein-labeled Caspase-3 specific substrate peptide Pep, loading chitosan and Toll-like receptor 4 antibody protein Anti-TLR4 covalently modified graphene oxide with hydroxycamptothecin to prepare graphene oxide/chitosan/Pep/Anti-TLR4/ hydroxycamptothecin with graphene oxide; (iii) judging the drug loading and release performance of graphene oxide/chitosan/Pep/Anti-TLR4/ hydroxycamptothecin by detecting the drug loading capacity, efficacy and release; and (iii) verifying the laser confocal experiment for the drug targeting of graphene oxide/chitosan/Pep/AntiTLR4/ hydroxycamptothecin and observing the efficacy of graphene oxide/chitosan/Pep/Anti-TLR4/ hydroxycamptothecin by detecting the content of inflammatory factors and related enzyme activities. USE - The method is useful for preparing and application of graphene oxide loaded hydroxycamptothecin nano-targeted drug useful for treating bovine mastitis. ADVANTAGE - The method produces nano-targeted drug with good stability. DETAILED DESCRIPTION - Preparing and application of graphene oxide loaded hydroxycamptothecin nano-targeted drug comprises (i) using graphene oxide as a carrier to complete the preparation of nano-targeted drugs through the modification of targeting molecules and the loading of drugs; (ii) using fluorescein-labeled Caspase-3 specific substrate peptide Pep, loading chitosan and Toll-like receptor 4 antibody protein Anti-TLR4 covalently modified graphene oxide with hydroxycamptothecin to prepare graphene oxide/chitosan/Pep/Anti-TLR4/ hydroxycamptothecin with graphene oxide as a carrier; (iii) judging the drug loading and release performance of graphene oxide/chitosan/Pep/Anti-TLR4/ hydroxycamptothecin by detecting the drug loading capacity, drug loading efficacy and drug release under different pH conditions; and (iii) verifying the laser confocal experiment for the drug targeting of graphene oxide/chitosan/Pep/AntiTLR4/ hydroxycamptothecin and observing the efficacy of graphene oxide/chitosan/Pep/Anti-TLR4/ hydroxycamptothecin by detecting the content of inflammatory factors and related enzyme activities